Skip to main content
. 2020 May 14;222(8):1334–1344. doi: 10.1093/infdis/jiaa254

Figure 2.

Figure 2.

Heterogeneity in markers of inflammation (by cirrhosis state and sex) at baseline and over the course of direct-acting antiviral (DAA) therapy. Left panels show inflammatory marker levels (median, interquartile range, and 5%/95% confidence intervals [CIs]) for all study participants as horizontal bar, box, and whiskers; x-axis labels represent time (weeks) from start of therapy, regardless of study arm or treatment duration. Middle panels show inflammatory marker levels for participants with sustained virologic response (SVR) by cirrhosis status (mean with 95% CI); x-axis labels indicate the times of sampling during and after therapy, with sample numbers indicated in insets. Right panels show inflammatory marker levels for participants with SVR by sex (mean with 95% CI); x-axis labels indicate the times during and after therapy, with sample numbers indicated in insets. Asterisks represent the first statistically significant differences, comparing baseline and time point during or after therapy (left panels) or comparing subgroups (middle and right panels). Panel A: IP-10; Panel B: Autotaxin; Panel C: Mac2BP; Panel D: IL-6. Abbreviations: ATX, autotaxin; IL-6, interleukin 6; IP-10, interferon-inducible protein 10; Mac2BP, Mac2-binding protein; PT, posttreatment.